Literature DB >> 18679416

Evidence for Hox and E2A-PBX1 collaboration in mouse T-cell leukemia.

J Bijl1, J Krosl, C-E Lebert-Ghali, J Vacher, N Mayotte, G Sauvageau.   

Abstract

Using murine Moloney leukemia virus (MMLV)-based proviral insertional mutagenesis, we previously showed a preferential targeting of a small region in the Hoxa gene locus in E2A-PBX1-induced lymphoid leukemia resulting in the overexpression of several Hoxa genes including Hoxa10, Hoxa9 and Hoxa7. This observation suggested a functional interaction between Hox gene overexpression and E2A-PBX1 in lymphoid tumors. To further explore this possibility, we generated a series of compound E2A-PBX1 x Hox transgenic mice and tested the genetic interaction between these genes in the generation of lymphoid leukemia in vivo. Results presented in this report show that the onset of T-cell leukemia is significantly accelerated in E2A-PBX1 x Hoxb4 compound transgenic animals when compared with control E2A-PBX1 or Hoxb4 littermates. Hoxa9 appears less potent than Hoxb4 to accelerate E2A-PBX1-induced T-cell leukemia in mice. E2A-PBX1-induced T-cell leukemias express much higher levels of Hoxa genes than MMLV-induced counterparts, possibly suggesting a contribution of these genes to T-cell transformation by E2A-PBX1. Collectively, these data provide the first genetic evidence showing oncogenic collaboration between E2A-PBX1 and a Hox gene in lymphoid malignancies in vivo and document the specific deregulation of a subgroup of Hoxa genes in these leukemias.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18679416     DOI: 10.1038/onc.2008.233

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Dual function of polycomb group proteins in differentiated murine T helper (CD4+) cells.

Authors:  Eyal Jacob; Reut Hod-Dvorai; Or Lea Ben-Mordechai; Yulia Boyko; Orly Avni
Journal:  J Mol Signal       Date:  2011-05-30

2.  Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8.

Authors:  Y Jiang; B Yan; W Lai; Y Shi; D Xiao; J Jia; S Liu; H Li; J Lu; Z Li; L Chen; X Chen; L Sun; K Muegge; Y Cao; Y Tao
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

3.  Identification of cooperative genes for E2A-PBX1 to develop acute lymphoblastic leukemia.

Authors:  Yasuyuki Sera; Norimasa Yamasaki; Hideaki Oda; Akiko Nagamachi; Linda Wolff; Takeshi Inukai; Toshiya Inaba; Hiroaki Honda
Journal:  Cancer Sci       Date:  2016-06-13       Impact factor: 6.716

4.  Oligomeric self-association contributes to E2A-PBX1-mediated oncogenesis.

Authors:  Chiou-Hong Lin; Zhong Wang; Jesús Duque-Afonso; Stephen Hon-Kit Wong; Janos Demeter; Alexander V Loktev; Tim C P Somervaille; Peter K Jackson; Michael L Cleary
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

5.  High WBP5 expression correlates with elevation of HOX genes levels and is associated with inferior survival in patients with acute myeloid leukaemia.

Authors:  C Ward; P Cauchy; P Garcia; J Frampton; M A Esteban; G Volpe
Journal:  Sci Rep       Date:  2020-02-26       Impact factor: 4.379

6.  Analysis of blood stem cell activity and cystatin gene expression in a mouse model presenting a chromosomal deletion encompassing Csta and Stfa2l1.

Authors:  Mélanie Bilodeau; Tara MacRae; Louis Gaboury; Jean-Philippe Laverdure; Marie-Pierre Hardy; Nadine Mayotte; Véronique Paradis; Sébastien Harton; Claude Perreault; Guy Sauvageau
Journal:  PLoS One       Date:  2009-10-19       Impact factor: 3.240

7.  Hoxb4 overexpression in CD4 memory phenotype T cells increases the central memory population upon homeostatic proliferation.

Authors:  Héloïse Frison; Gloria Giono; Paméla Thébault; Marilaine Fournier; Nathalie Labrecque; Janet J Bijl
Journal:  PLoS One       Date:  2013-12-06       Impact factor: 3.240

Review 8.  Genetically engineered mouse models of human B-cell precursor leukemias.

Authors:  Julia Hauer; Arndt Borkhardt; Isidro Sánchez-García; César Cobaleda
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.